Transplant International最新文献_第7页

ABO incompatible LRD kidney transplantation should be offered to children: results from a 33-year comparative OPTN study. ABO血型不相容的LRD肾移植应该提供给儿童：来自一项33年比较OPTN研究的结果

IF 3.6 3区医学

Transplant International Pub Date : 2026-08-17 eCollection Date: 2026-01-01 DOI: 10.3389/ti.2026.16723

Alicia Paessler, Ioannis Loukopoulos, Pankaj Chandak, Nicos Kessaris, Jelena Stojanovic

{"title":"ABO incompatible LRD kidney transplantation should be offered to children: results from a 33-year comparative OPTN study.","authors":"Alicia Paessler, Ioannis Loukopoulos, Pankaj Chandak, Nicos Kessaris, Jelena Stojanovic","doi":"10.3389/ti.2026.16723","DOIUrl":"10.3389/ti.2026.16723","url":null,"abstract":"ABOi transplantation is a growing practice with excellent clinical outcomes. Some paediatric transplant programmes are reluctant to offer ABOi transplantation and list children on a DD waiting list. However, there are no studies directly comparing the outcomes between pediatric ABOi LD kidney transplants (LDKTx) and ABOc DD transplants (DDKTx). Data were retrieved on all pediatric kidney transplants from 1987-2020, from the United Network for Organ Sharing. Propensity score matching was used to select a control group of ABOc transplant recipients. Long term outcomes were compared between ABOi and ABOc kidney transplants and between ABOi LDKTx and ABOc DDKTx. Data were compared using chi-square test, t-test and Kaplan-Meier survival analysis. Overall, there were 70 pediatric ABOi kidney transplants meeting the study criteria. There was no significant difference in allograft (p = 0.42) and patient survival (p = 0.58) between ABOi and ABOc transplants. ABOi LDKTx had significantly lower incidence of delayed allograft function and better long-term allograft survival than ABOc DDKTx (p < 0.01, p = 0.01). ABOi transplantation has excellent long-term outcomes. ABOi LDKTx lead to better long-term outcomes than ABOc DDKTx. We recommend that ABOi transplantation from a LD should be considered prior to listing children for transplantation from a DD.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"39 ","pages":"16723"},"PeriodicalIF":3.6,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13528432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of tacrolimus peak concentration on kidney graft outcomes. 他克莫司峰值浓度对肾移植预后的影响。

IF 3.6 3区医学

Transplant International Pub Date : 2026-08-17 eCollection Date: 2026-01-01 DOI: 10.3389/ti.2026.16212

Quentin Monchal, Guillaume Claisse, Nicolas Maillard, Christophe Mariat

{"title":"Impact of tacrolimus peak concentration on kidney graft outcomes.","authors":"Quentin Monchal, Guillaume Claisse, Nicolas Maillard, Christophe Mariat","doi":"10.3389/ti.2026.16212","DOIUrl":"10.3389/ti.2026.16212","url":null,"abstract":"Low tacrolimus (Tac) trough concentration-to-dose ratio (C0/D ratio) identifies kidney transplant patients with high level of Tac metabolization and is associated with poorer outcomes. We hypothesized that fast metabolization is associated with higher maximal Tac blood concentration (Cmax) and that Tac Cmax has a detrimental effect by itself. We retrospectively selected consecutive kidney transplant patients who (i) were treated by Tac, (ii) had systematic pharmacokinetic evaluation at 3- and 12-month posttransplant, and (iii) with a minimal follow-up of 5 years. Association between Tac Cmax/C0 with traditional transplant outcomes was analysed. 519 patients with a median follow-up of 8 years were included. Fast metabolizers displayed significantly higher median Cmax (20 vs. 17 ng/mL p < 0.001). Death-censored graft survival (DCGS) was significantly lower for patients with the highest Cmax/C0 values (Log rank, p = 0.05). In multivariate cox analysis, higher Cmax/C0 was independently associated with DCGS (HR = 1.37 [1.01; 1.87], p = 0.043). Our data support the hypothesis that exposure to high Cmax is detrimental and that fast metabolizers exhibit higher Tac Cmax even in situations where Tac C0 is not elevated. Tac formulations prone to mitigate pharmacokinetic peak could thus be particularly beneficial to fast metabolizers and should be evaluated in this indication.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"39 ","pages":"16212"},"PeriodicalIF":3.6,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-transplant HbA1c and BMI are associated with long-term survival after lung transplantation. 移植前HbA1c和BMI与肺移植后的长期生存相关。

IF 3.6 3区医学

Transplant International Pub Date : 2026-08-13 eCollection Date: 2026-01-01 DOI: 10.3389/ti.2026.16741

Zsofia Rosselli, Luca Saccarello, Andrea Macedo, Thomas Gaisl, Carolin Steinack, Fabrizio Pumo, Nail Atasayar, Georg Lang, Ömer Senbaklavaci, Isabelle Opitz, Irina Lea Dubach, Silvia Ulrich, Julian Müller, René Hage, Macé Matthew Schuurmans

引用次数: 0

Findings and significance of early follow-up biopsies after treatment of acute rejection in kidney transplant recipients. 肾移植受者急性排斥反应治疗后早期随访活检的发现和意义。

IF 3.6 3区医学

Transplant International Pub Date : 2026-08-13 eCollection Date: 2026-01-01 DOI: 10.3389/ti.2026.16296

Amanda Ahlmark, Kaisa Ahopelto, Anne Räisänen-Sokolowski, Jouni Lauronen, Marko Lempinen, Ville Sallinen, Ilkka Helanterä

{"title":"Findings and significance of early follow-up biopsies after treatment of acute rejection in kidney transplant recipients.","authors":"Amanda Ahlmark, Kaisa Ahopelto, Anne Räisänen-Sokolowski, Jouni Lauronen, Marko Lempinen, Ville Sallinen, Ilkka Helanterä","doi":"10.3389/ti.2026.16296","DOIUrl":"10.3389/ti.2026.16296","url":null,"abstract":"Treatment resistant acute rejection after kidney transplantation is linked to inferior outcomes, yet many centers do not routinely perform follow-up biopsies. The optimal timing of such biopsies remains uncertain. We evaluated findings from follow-up biopsies performed ≤45 days after treatment of acute rejection and assessed their association with long-term outcomes. Adult kidney transplants performed from 01/2014 to 07/2024 were included (n = 2,420). Acute rejections were classified according to Banff criteria. T-cell-mediated rejection, including borderline TCMR changes, was treated with pulse steroids; antibody-mediated rejection was treated with steroids, intravenous immunoglobulin, and plasma exchange. Findings from follow-up biopsies taken ≤45 days after treatment of early acute rejection were correlated with graft outcomes. Of 383 patients (16%) with acute rejection within 3 months post-transplant, 221 underwent a follow-up biopsy ≤45 days. Of these, 50% were taken by protocol and 50% because of clinical reasons. In 164 cases (74%), rejection changes had resolved. At 1-year, median creatinine was 1.3 mg/dL in those without rejection, 1.6 mg/dL in patients with persistent changes, and 1.5 mg/dL in those with resolved changes. Persistent histologic rejection within 45 days was associated with inferior long-term graft survival.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"39 ","pages":"16296"},"PeriodicalIF":3.6,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Innovative diagnostics and treatments of infections in transplantation," report from the 2025 spring highlights in transplantation sciences meeting. “移植感染的创新诊断和治疗”，来自2025年春季移植科学会议的报告。

IF 3.6 3区医学

Transplant International Pub Date : 2026-08-10 eCollection Date: 2026-01-01 DOI: 10.3389/ti.2026.16562

Jacques Fourgeaud, Benedicte Neven, Nassim Kamar, Imane Farhat, Oriol Manuel, Martina Sester, Lionel Couzi, David Boutboul, Sophie Caillat Zucman, Jean Daniel Lelievre, Marie-Benedicte Le Stang, Marion Le Maréchal, Hélène François, Durrbach Antoine, Julien Zuber, Hannah Kaminski

{"title":"\"Innovative diagnostics and treatments of infections in transplantation,\" report from the 2025 spring highlights in transplantation sciences meeting.","authors":"Jacques Fourgeaud, Benedicte Neven, Nassim Kamar, Imane Farhat, Oriol Manuel, Martina Sester, Lionel Couzi, David Boutboul, Sophie Caillat Zucman, Jean Daniel Lelievre, Marie-Benedicte Le Stang, Marion Le Maréchal, Hélène François, Durrbach Antoine, Julien Zuber, Hannah Kaminski","doi":"10.3389/ti.2026.16562","DOIUrl":"10.3389/ti.2026.16562","url":null,"abstract":"Infectious complications remain a leading cause of morbidity and mortality after solid organ transplantation, driven by profound immunosuppression, emerging pathogens, and increasing antiviral resistance. The 2025 Spring Highlights in Transplantation Sciences (HITS) meeting, held in Paris under the auspices of the Société Francophone de Transplantation and endorsed by the European Society of Organ Transplantation, brought together international experts to discuss recent advances in the diagnosis, pathogenesis, prevention, and treatment of infections in transplant recipients. This report summarizes the key scientific presentations covering innovative approaches to viral hepatitis, cytomegalovirus (CMV), Epstein-Barr virus, human herpesvirus-8, BK polyomavirus, infectious encephalitis, and vaccination strategies. Particular emphasis was placed on the growing role of metagenomic next-generation sequencing for diagnosing unexplained infections, the integration of immune monitoring into clinical decision-making, and the development of adoptive cellular therapies, including virus-specific αβ T cells and γδ T-cell-based immunotherapies for refractory CMV infection. The meeting also highlighted emerging concepts in donor-recipient immunogenetics, novel diagnostic technologies, and personalized preventive strategies. Collectively, these advances illustrate the transition toward precision medicine in transplant infectious diseases, combining cutting-edge diagnostics, immune profiling, and innovative immunotherapeutic approaches to improve the management and outcomes of solid organ transplant recipients.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"39 ","pages":"16562"},"PeriodicalIF":3.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13500380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148814221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond the acceptance decision: integrating genetic findings into lifelong living donor care. 在接受决定之外：将基因发现整合到终身活体捐赠者护理中。

IF 3.6 3区医学

Transplant International Pub Date : 2026-08-06 eCollection Date: 2026-01-01 DOI: 10.3389/ti.2026.17017

Stefan Reuter, Daniela A Braun, Klemens Budde, Barbara Suwelack

引用次数: 0

Secondary thrombotic microangiopathy following lung transplantation: a multicenter European cohort study. 肺移植后继发血栓性微血管病：一项多中心欧洲队列研究。

IF 3.6 3区医学

Transplant International Pub Date : 2026-08-05 eCollection Date: 2026-01-01 DOI: 10.3389/ti.2026.16046

Zsofia Rosselli, Jan Havlin, Berta Saez-Gimenez, François M Carlier, Gabriella Muraközy, Peter Jaksch, Stefan Schwarz, Dominik Damm, Mace Schuurmans, Nicolas Kozakowski, Martina Gaggl, Alice Schmidt, Gere Sunder-Plassmann, Christof Aigner

{"title":"Secondary thrombotic microangiopathy following lung transplantation: a multicenter European cohort study.","authors":"Zsofia Rosselli, Jan Havlin, Berta Saez-Gimenez, François M Carlier, Gabriella Muraközy, Peter Jaksch, Stefan Schwarz, Dominik Damm, Mace Schuurmans, Nicolas Kozakowski, Martina Gaggl, Alice Schmidt, Gere Sunder-Plassmann, Christof Aigner","doi":"10.3389/ti.2026.16046","DOIUrl":"10.3389/ti.2026.16046","url":null,"abstract":"Secondary thrombotic microangiopathy (sTMA) is a rare but severe complication after lung transplantation. We performed a multicenter retrospective cohort study including adult lung transplant recipients diagnosed with de novo sTMA between 2010 and 2023 across five European transplant centers. The primary outcome was incidence of sTMA, with secondary outcomes including clinical presentation, treatment strategies, renal outcomes, and survival. Among 3,747 lung transplantations, 49 cases of sTMA were identified, corresponding to an incidence of 1.33%. Median time to diagnosis was 312 days (IQR 93-546), with 53% occurring within the first post-transplant year. All patients presented with acute kidney injury and laboratory signs of hemolysis, neurological complications were observed in 8%. Therapeutic approaches included plasma exchange (46.9%), anti-C5 therapy (24.5%), and sequential plasma exchange followed by complement inhibition (10.2%). At follow-up, 65.3% developed chronic kidney disease, 20.4% progressed to end-stage renal disease, and 10.2% died during the acute episode. No significant association between treatment modality and renal or survival outcomes was observed. sTMA after lung transplantation is infrequent but associated with substantial renal morbidity and mortality. Early recognition through assessment of hemolysis and kidney injury, supported by renal biopsy in selected cases, may facilitate timely diagnosis and management.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"39 ","pages":"16046"},"PeriodicalIF":3.6,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13485827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revealing the potential of non-transplanted donor organs: a comparative analysis in the Eurotransplant region. 揭示未移植供体器官的潜力：欧洲移植地区的比较分析。

IF 3.6 3区医学

Transplant International Pub Date : 2026-08-03 eCollection Date: 2026-01-01 DOI: 10.3389/ti.2026.16516

A Kofler, F J Krendl, L Prommegger, J Hofmann, A Weissenbacher, B Cardini, A T Meszaros, T Resch, G Brandacher, T Hautz, R Oberhuber, E de Buijzer, S Eschertzhuber, S Schneeberger

{"title":"Revealing the potential of non-transplanted donor organs: a comparative analysis in the Eurotransplant region.","authors":"A Kofler, F J Krendl, L Prommegger, J Hofmann, A Weissenbacher, B Cardini, A T Meszaros, T Resch, G Brandacher, T Hautz, R Oberhuber, E de Buijzer, S Eschertzhuber, S Schneeberger","doi":"10.3389/ti.2026.16516","DOIUrl":"https://doi.org/10.3389/ti.2026.16516","url":null,"abstract":"Post-mortem organ donation is essential for modern transplantation medicine, yet a substantial proportion of recovered donor organs are not transplanted. These organs, although clinically declined, hold significant and untapped value for biomedical research and technological innovation. Eurotransplant reports and United States national data were reviewed to quantify transplanted and not used organs and to assess temporal trends. During the study period, 100,260 organs were reported in Eurotransplant, of which 32,242 (32.16%) were not transplanted. Of all reported organs, 16.05% were accepted for transplantation but not used, representing a stable and predictable number of organs suitable for secondary research use. A review of international, European, and national legislation demonstrated that, in many Eurotransplant countries, existing laws focus almost exclusively on transplantation and provide limited guidance on the research use of non-transplanted organs, with the Netherlands, Slovenia, Luxembourg, and partially Belgium as notable exceptions. Emerging technologies highlight the scientific and clinical relevance of these organs. Establishing legal and ethical pathways for their secondary use could reduce organ wastage, support innovation, and improve transplantation outcomes. Engagement with the Austrian Federal Ministry of Health, informed by the findings of this work, contributed to an amendment of the Austrian Organ Transplantation Act.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"39 ","pages":"16516"},"PeriodicalIF":3.6,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13478019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ABO-incompatibility and hepatocellular carcinoma recurrence after living donor liver transplantation: stratified by tumor burden. abo血型不相容与肝移植术后肝癌复发：按肿瘤负荷分层。

IF 3.6 3区医学

Transplant International Pub Date : 2026-08-03 eCollection Date: 2026-01-01 DOI: 10.3389/ti.2026.17121

Woo-Hyoung Kang, Shin Hwang, Deok-Bog Moon, Ki-Hun Kim, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Byeong-Gon Na, Sang-Hoon Kim, Sung-Min Kim, Sung-Gyu Lee

{"title":"ABO-incompatibility and hepatocellular carcinoma recurrence after living donor liver transplantation: stratified by tumor burden.","authors":"Woo-Hyoung Kang, Shin Hwang, Deok-Bog Moon, Ki-Hun Kim, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Byeong-Gon Na, Sang-Hoon Kim, Sung-Min Kim, Sung-Gyu Lee","doi":"10.3389/ti.2026.17121","DOIUrl":"https://doi.org/10.3389/ti.2026.17121","url":null,"abstract":"ABO-incompatible (ABOi) living donor liver transplantation (LDLT) requires rituximab-based desensitization and intensified early immunosuppression, and whether this promotes hepatocellular carcinoma (HCC) recurrence remains controversial. We hypothesized that this effect depends on tumor burden, assessed morphologically (Milan criteria) and biologically (ADV score). In this single-center study, we analyzed 1,573 adults transplanted for HCC (ABOi, n = 316; ABO-compatible [ABOc], n = 1,257); the primary endpoint was recurrence-free survival (RFS). Crude recurrence was similar (21.8% vs. 20.7%; P = 0.64) despite a lower tumor burden in ABOi recipients. In a propensity score-matched cohort, RFS did not differ overall (hazard ratio 1.11, 95% CI 0.82-1.48), but beyond Milan recurrence was higher in ABOi recipients (53.7% vs. 38.5%; adjusted HR 1.45, 95% CI 1.00-2.09), whereas within Milan it was identical (13.3% vs. 13.4%). The same pattern held for tumor biology: recurrence was higher in ABOi only at ADV ≥5log (64.0% vs. 44.6%; P = 0.022). Higher early tacrolimus exposure in ABOi recipients was associated with recurrence. Overall survival was similar (P = 0.91). ABO-incompatibility did not compromise survival. Recurrence was higher in ABOi recipients with a high tumor burden by either measure, although the formal interaction tests were not significant (P = 0.23 and P = 0.088). These exploratory subgroup findings are hypothesis-generating and support closer early surveillance.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"39 ","pages":"17121"},"PeriodicalIF":3.6,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13478018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gaza: not to act is to act. 加沙：不行动就是行动。

IF 3.6 3区医学

Transplant International Pub Date : 2026-07-31 eCollection Date: 2026-01-01 DOI: 10.3389/ti.2026.16534

Nizam Mamode, Susanna Fernandez-Diaz, Rola Tubail, Khaled Masoud, Walid Masoud

引用次数: 0